Vanguard Discloses 6.7% Passive Stake in Boston Scientific
Ticker: BSX · Form: SC 13G/A · Filed: Feb 13, 2024 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | SC 13G/A |
| Filed Date | Feb 13, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investing, amendment, medical-devices
TL;DR
**Vanguard still owns 6.7% of Boston Scientific, showing continued passive confidence.**
AI Summary
The Vanguard Group, a major investment firm, filed an amendment (SC 13G/A) on February 13, 2024, disclosing its ownership in Boston Scientific Corp. As of December 29, 2023, Vanguard beneficially owned 99,499,349 shares of Boston Scientific's Common Stock, representing 6.7% of the company. This filing indicates Vanguard's continued significant, but passive, stake in Boston Scientific, which is important for investors as it shows a large institutional holder maintains confidence in the company without seeking to influence management.
Why It Matters
This filing confirms that a major institutional investor, Vanguard, holds a substantial portion of Boston Scientific, signaling long-term confidence without active management intervention. For investors, this means a significant player believes in the company's value, but isn't pushing for strategic changes.
Risk Assessment
Risk Level: low — This filing is routine for large institutional investors and indicates a stable, passive ownership stake, posing minimal risk.
Analyst Insight
Investors should note Vanguard's continued significant, passive stake as a sign of institutional confidence, but understand it doesn't imply any upcoming strategic changes or activist pressure from Vanguard.
Key Numbers
- 99,499,349 — Shares Beneficially Owned (The total number of Boston Scientific Common Stock shares owned by The Vanguard Group as of December 29, 2023.)
- 6.7% — Percentage of Class (The percentage of Boston Scientific's Common Stock owned by The Vanguard Group, indicating a significant but non-controlling stake.)
Key Players & Entities
- The Vanguard Group (company) — reporting person and beneficial owner
- Boston Scientific Corp (company) — subject company whose securities are being reported
- 99,499,349 shares (dollar_amount) — number of shares beneficially owned by Vanguard
- 6.7% (dollar_amount) — percentage of Boston Scientific's class of securities owned by Vanguard
- December 29, 2023 (date) — date of the event requiring the filing
- February 13, 2024 (date) — filing date of the SC 13G/A
Forward-Looking Statements
- Vanguard will maintain a significant, passive ownership stake in Boston Scientific Corp. (The Vanguard Group) — high confidence, target: Next 12-24 months
FAQ
What type of filing is this and who filed it?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It was filed by The Vanguard Group, a major investment management company.
What company's stock is being reported in this filing?
The filing reports on the Common Stock of Boston Scientific Corp, identified by CUSIP Number 101137107.
How many shares of Boston Scientific does Vanguard beneficially own, and what percentage does that represent?
As of December 29, 2023, The Vanguard Group beneficially owned 99,499,349 shares of Boston Scientific Corp Common Stock, which represents 6.7% of the class of securities.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required the filing of this statement was December 29, 2023.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), which typically applies to institutional investors who acquire beneficial ownership of more than 5% of a class of a company's equity securities in the ordinary course of business and without the purpose or effect of changing or influencing control of the issuer.
Filing Stats: 809 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-02-13 17:00:46
Filing Documents
- tv0462-bostonscientificcorp.htm (SC 13G/A) — 11KB
- 0001104659-24-020459.txt ( ) — 13KB
(a) - Name of Issuer
Item 1(a) - Name of Issuer: Boston Scientific Corp
(b) - Address of Issuer's Principal Executive Offices
Item 1(b) - Address of Issuer's Principal Executive Offices: 300 Boston Scientific Way Marlborough, MA 01752-1234
(a) - Name of Person Filing
Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930
(b) – Address of Principal Business Office or, if none, residence
Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355
(c) – Citizenship
Item 2(c) – Citizenship: Pennsylvania
(d) - Title of Class of Securities
Item 2(d) - Title of Class of Securities: Common Stock
(e) - CUSIP Number
Item 2(e) - CUSIP Number 101137107
- Type of Filing
Item 3 - Type of Filing: This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).
- Ownership
Item 4 - Ownership: (a) Amount Beneficially Owned: (b) Percent of Class: (c) Number of shares as to which such person has: (i) sole power to vote or direct to vote: (ii) shared power to vote or direct to vote: (iii) sole power to dispose of or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Comments: The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.
- Ownership of Five Percent or Less of a Class
Item 5 - Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following
- Ownership of More Than Five Percent on Behalf of Another Person
Item 6 - Ownership of More Than Five Percent on Behalf of Another Person: The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%. Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company: Not applicable
- Identification and Classification of Members of Group
Item 8 - Identification and Classification of Members of Group: Not applicable
- Notice of Dissolution of Group
Item 9 - Notice of Dissolution of Group: Not applicable
- Certification
Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 By /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration